Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Pharmacology and Therapeutics

• Publication date

  2014-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.pharmthera.2014.07.003PMID 25050922
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).

  2014cited by this paper
• Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study.

  2014cited by this paper
• Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

  2014cited by this paper
• HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: impact of the HLA-G 14 base pair (rs66554220) polymorphism

  2014cited by this paper
• A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor

  2014cited by this paper
• Endothelin-1 Promotes Survival and Chemoresistance in Chronic Lymphocytic Leukemia B Cells through ETA Receptor

  2014cited by this paper
• The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization.

  2014cited by this paper
• Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.

  2014cited by this paper
• IGHV1-69 B Cell Chronic Lymphocytic Leukemia Antibodies Cross-React with HIV-1 and Hepatitis C Virus Antigens as Well as Intestinal Commensal Bacteria

  2014cited by this paper
• Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study

  2014cited by this paper
• BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity

  2014cited by this paper
• Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia.

  2014cited by this paper
• Lyn-mediated procaspase 8 dimerization blocks apoptotic signaling in B-cell chronic lymphocytic leukemia.

  2014cited by this paper
• Development and characterization of a physiologically relevant model of lymphocyte migration in chronic lymphocytic leukemia.

  2014cited by this paper
• Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

  2014cited by this paper
• IPI-145 shows promise in CLL patients.

  2014cited by this paper
• Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor.

  2013cited by this paper
• Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.

  2013cited by this paper
• The PI3-Kinase Delta Inhibitor Idelalisib (GS-1101) Targets Integrin-Mediated Adhesion of Chronic Lymphocytic Leukemia (CLL) Cell to Endothelial and Marrow Stromal Cells

  2013cited by this paper
• A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi

  2013cited by this paper
• CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia.

  2013cited by this paper
• Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia.

  2013cited by this paper
• T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production.

  2013cited by this paper
• Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

  2013cited by this paper
• CLL B-cell receptors can recognize themselves: alternative epitopes and structural clues for autostimulatory mechanisms in CLL.

  2013cited by this paper
• Update on a phase I study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL.

  2013cited by this paper
• A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

  2013cited by this paper
• Ibrutinib In Combination With Bendamustine and Rituximab Is Active and Tolerable In Patients With Relapsed/Refractory CLL/SLL: Final Results Of a Phase 1b Study

  2013cited by this paper
• Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide.

  2013cited by this paper
• Single Agent Ibrutinib (PCI-32765) Achieves Equally Good and Durable Responses In Chronic Lymphocytic Leukemia (CLL) Patients With and Without Deletion 17p

  2013cited by this paper
• Ibrutinib In Combination With Rituximab (iR) Is Well Tolerated and Induces a High Rate Of Durable Remissions In Patients With High-Risk Chronic Lymphocytic Leukemia (CLL): New, Updated Results Of a Phase II Trial In 40 Patients

  2013cited by this paper
• Modeling Tumor-Host Interactions of Chronic Lymphocytic Leukemia in Xenografted Mice to Study Tumor Biology and Evaluate Targeted Therapy

  2013cited by this paper
• Targeting pathological B cell receptor signalling in lymphoid malignancies

  2013cited by this paper
• Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib.

  2013cited by this paper
• Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications.

  2013cited by this paper
• Protein Kinase C-β-Dependent Activation of NF-κB in Stromal Cells Is Indispensable for the Survival of Chronic Lymphocytic Leukemia B Cells In Vivo

  2013cited by this paper
• Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

  2013cited by this paper
• Regulatory T-cells in B-cell chronic lymphocytic leukemia: their role in disease progression and autoimmune cytopenias

  2013cited by this paper
• Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function.

  2013cited by this paper
• Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia.

  2013cited by this paper
• Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing.

  2013cited by this paper
• The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation

  2013cited by this paper
• Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity.

  2013cited by this paper
• The phosphatidylinositol‐3 kinase I inhibitor BKM120 induces cell death in B‐chronic lymphocytic leukemia cells in vitro

  2013cited by this paper
• Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response

  2012cited by this paper
• The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.

  2012cited by this paper
• Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukemia.

  2012cited by this paper
• Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells.

  2012cited by this paper
• The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.

  2012cited by this paper
• Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies.

  2012cited by this paper
• Overexpression of the autoimmunity-associated phosphatase PTPN22 promotes survival of antigen-stimulated CLL cells by selectively activating AKT.

  2012cited by this paper
• Physical contact with endothelial cells through β1- and β2- integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells

  2012cited by this paper
• Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration

  2012cited by this paper
• Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia.

  2012cited by this paper
• Mimicking the tumour microenvironment: three different co‐culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells

  2012cited by this paper
• Self-antigen recognition by follicular lymphoma B-cell receptors.

  2012cited by this paper
• Antigen receptor stereotypy across B-cell lymphoproliferations: the case of IGHV4-59/IGKV3-20 receptors with rheumatoid factor activity

  2012cited by this paper
• The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells

  2012cited by this paper
• High expression of tumor-infiltrating macrophages correlates with poor prognosis in patients with diffuse large B-cell lymphoma

  2012cited by this paper
• Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.

  2012cited by this paper
• Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance

  2012cited by this paper
• Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia

  2012cited by this paper
• RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans.

  2012cited by this paper
• Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

  2012cited by this paper
• Stromal Endothelial Cells Establish a Bidirectional Crosstalk with Chronic Lymphocytic Leukemia Cells through the TNF-Related Factors BAFF, APRIL, and CD40L

  2012cited by this paper
• Primary B-CLL Resistance to NK Cell Cytotoxicity can be Overcome In Vitro and In Vivo by Priming NK Cells and Monoclonal Antibody Therapy

  2012cited by this paper
• MicroRNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia

  2011cited by this paper
• Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling

  2011cited by this paper
• Inflammatory cytokines and signaling pathways are associated with survival of primary chronic lymphocytic leukemia cells in vitro: a dominant role of CCL2

  2011cited by this paper
• CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.

  2011cited by this paper
• The seed and soil hypothesis revisited—The role of tumor‐stroma interactions in metastasis to different organs

  2011cited by this paper
• Investigating the role of CD38 and functionally related molecular risk factors in the CLL NOD/SCID xenograft model

  2011cited by this paper
• Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

  2011influential reference
• The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy.

  2011cited by this paper
• Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro‐survival microenvironmental signals

  2011cited by this paper
• B-cell receptor signaling in chronic lymphocytic leukemia.

  2011influential reference
• Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia.

  2011cited by this paper
• Differential Bone Marrow Homing Capacity of VLA-4 and CD38 High Expressing Chronic Lymphocytic Leukemia Cells

  2011cited by this paper
• CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia.

  2011cited by this paper
• Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.

  2011cited by this paper
• Lyn-mediated SHP-1 recruitment to CD5 contributes to resistance to apoptosis of B-cell chronic lymphocytic leukemia cells

  2011cited by this paper
• Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

  2011cited by this paper
• Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3.

  2011cited by this paper
• The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.

  2011cited by this paper
• The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.

  2011cited by this paper
• Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.

  2011cited by this paper
• Preliminary Results From A Phase I Dose Escalation Study to Determine the Maximum Tolerated Dose of Plerixafor In Combination with Rituximab In Patients with Relapsed Chronic Lymphocytic Leukemia

  2010cited by this paper
• Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

  2010cited by this paper
• Elucidating the CXCL12/CXCR4 Signaling Network in Chronic Lymphocytic Leukemia through Phosphoproteomics Analysis

  2010cited by this paper
• Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

  2010cited by this paper
• Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression.

  2010cited by this paper
• An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.

  2010cited by this paper
• Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.

  2010cited by this paper
• Stereotypical Chronic Lymphocytic Leukemia B-Cell Receptors Recognize Survival Promoting Antigens on Stromal Cells

  2010cited by this paper
• Surface IgM of CLL cells displays unusual glycans indicative of engagement of antigen in vivo.

  2010cited by this paper
• Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

  2010cited by this paper
• Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin.

  2010cited by this paper
• Activities of SYK and PLCγ2 Predict Apoptotic Response of CLL Cells to SRC Tyrosine Kinase Inhibitor Dasatinib

  2010cited by this paper
• Soluble CD14 is a novel monocyte-derived survival factor for chronic lymphocytic leukemia cells, which is induced by CLL cells in vitro and present at abnormally high levels in vivo.

  2010cited by this paper
• The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells

  2009cited by this paper

• A spheroid model that recapitulates the protective role of the lymph node microenvironment and serves as a platform for drug testing in chronic lymphocytic leukemia

  2025cites this paper
• The survival grip–how cell adhesion promotes tumor maintenance within the microenvironment

  2024cites this paper
• Clinical trials, challenges, and changes in TCR-based therapeutics for hematologic malignancies

  2024cites this paper
• Extracellular vesicles from type-2 macrophages increase the survival of chronic lymphocytic leukemia cells ex vivo

  2024cites this paper
• Lysosome-Disrupting Agents in Combination with Venetoclax Increase Apoptotic Response in Primary Chronic Lymphocytic Leukemia (CLL) Cells Mediated by Lysosomal Cathepsin D Release and Inhibition of Autophagy

  2024cites this paper
• Lessons learned from the Eµ-TCL1 mouse model of CLL.

  2024cites this paper
• CCL3 as Possible Negative Prognostic Factor in Chronic Lymphocytic Leukemia

  2023cites this paper
• PYK2 is overexpressed in chronic lymphocytic leukaemia: A potential new therapeutic target

  2023cites this paper
• Electron transport chain and mTOR inhibition synergistically decrease CD40 signaling and counteract venetoclax resistance in chronic lymphocytic leukemia

  2023cites this paper
• Protein Phosphorylation and Redox Status: An as Yet Elusive Dyad in Chronic Lymphocytic Leukemia

  2022cites this paper
• A synthetic human 3D in vitro lymphoid model enhancing B-cell survival and functional differentiation

  2022cites this paper
• The contributory roles of the CXCL12/CXCR4/CXCR7 axis in normal and malignant hematopoiesis: A possible therapeutic target in hematologic malignancies.

  2022cites this paper
• Shared genomic segment analysis in a large high-risk chronic lymphocytic leukemia pedigree implicates CXCR4 in inherited risk

  2021cites this paper
• Role of Par-4 in B-Cell Hematological Malignancies

  2021cites this paper
• Protein kinase C‐β‐dependent changes in the glucose metabolism of bone marrow stromal cells of chronic lymphocytic leukemia

  2021cites this paper
• RGDS-Modified Superporous Poly(2-Hydroxyethyl Methacrylate)-Based Scaffolds as 3D In Vitro Leukemia Model

  2021cites this paper
• Immune modulatory effects of Idelalisib in stromal cells of chronic lymphocytic leukemia

  2021cites this paper
• Stem Cells and Extracellular Vesicles: Biological Regulators of Physiology and Disease

  2020cites this paper
• High M-MDSC Percentage as a Negative Prognostic Factor in Chronic Lymphocytic Leukaemia

  2020cites this paper
• Co-expression network-based identification of biomarkers correlated with the lymph node metastasis of patients with head and neck squamous cell carcinoma

  2020cites this paper
• Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL

  2020cites this paper
• Monocytic MDSC as a source of immunosuppressive cytokines in chronic lymphocytic leukemia (CLL) microenvironment.

  2020cites this paper
• Targeting the A2A adenosine receptor counteracts immunosuppression in vivo in a mouse model of chronic lymphocytic leukemia

  2020cites this paper
• Stem Cells & Extracellular Vesicles in Physiology & Disease.

  2019cites this paper
• Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia

  2019cites this paper
• SLAMF receptors on normal and malignant B cells.

  2019cites this paper
• SLAMF1/CD150 in hematologic malignancies: Silent marker or active player?

  2019cites this paper
• Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib drug response in chronic lymphocytic leukemia

  2019cites this paper
• A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression

  2018cites this paper
• Circulating Tfh1 (cTfh1) cell numbers and PD1 expression are elevated in low-grade B-cell non-Hodgkin’s lymphoma and cTfh gene expression is perturbed in marginal zone lymphoma

  2018cites this paper
• GPCRomics: GPCR Expression in Cancer Cells and Tumors Identifies New, Potential Biomarkers and Therapeutic Targets

  2018cites this paper
• Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells

  2018cites this paper
• Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies.

  2018cites this paper
• Plasma matrix metalloprotease 9 correlates with blood lymphocytosis, leukemic cell invasiveness, and prognosis in B-cell chronic lymphocytic leukemia

  2017cites this paper
• Extracellular vesicles of bone marrow stromal cells rescue chronic lymphocytic leukemia B cells from apoptosis, enhance their migration and induce gene expression modifications

  2017cites this paper
• CD84 mediates CLL-microenvironment interactions

  2017cites this paper
• Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia

  2017cites this paper
• Bruton's tyrosine kinase inhibitor restrains Wnt signaling in chronic lymphocytic leukemia.

  2016cites this paper
• Key Molecular Drivers of Chronic Lymphocytic Leukaemia (CLL)

  2016cites this paper
• Key Molecular Drivers of Chronic Lymphocytic Leukemia.

  2016cites this paper
• Preclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the trade.

  2016cites this paper
• Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics

  2016cites this paper
• In vivo adhesion of malignant B cells to bone marrow microvasculature is regulated by α4β1 cytoplasmic-binding proteins

  2016cites this paper
• Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia

  2016cites this paper
• resistance to BTKi and PI3K d i in CLL

  2016cites this paper
• IL-4, IgM, and resistance to BTKi and PI3Kδi in CLL.

  2016cites this paper
• Targeted therapies for CLL: Practical issues with the changing treatment paradigm.

  2016cites this paper
• Lipoprotein lipase in chronic lymphocytic leukemia: function and prognostic implications

  2016cites this paper
• Phosphatidylinositol-3,4-Bisphosphate and Its Binding Protein Lamellipodin Regulate Chemotaxis of Malignant B Lymphocytes

  2016influential citation
• Investigation into the efficacy of the anti-CD20 monoclonal antibody ofatumumab in chronic lymphocytic leukaemia

  2015cites this paper
• Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways

  2015influential citation
• Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A.

  2015cites this paper
• The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia.

  2015cites this paper
• Initial treatment of CLL: integrating biology and functional status.

  2015cites this paper
• Disruption of in vivo Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study

  2015cites this paper
• Expression and function of the TL1A/DR3 axis in chronic lymphocytic leukemia

  2015cites this paper
• The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6.

  2015cites this paper
• Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway

  2015cites this paper
• Targeting PI3Kδ: Emerging Therapy for Chronic Lymphocytic Leukemia and Beyond

  2015cites this paper
• Etudes des altérations fonctionnelles de la signalisation dépendante du récepteur à l’antigène dans les cellules B de la Leucémie Lymphoïde Chronique

  2015influential citation
• Targeted therapy and outcome in chronic lymphocytic leukemia

  2014cites this paper
• Regulation of malignant B cell migration by PI(3,4)P2-specific phosphatases and binding proteins

  2013influential citation